Table 2.
Alphavirus vaccine candidates in advanced clinical development
| Type of vaccine | Vaccine candidate | Clinical trial sponsor | Clinical trial identifier |
|---|---|---|---|
| Live-attenuated |
VLA1553 (CHIKV) VEE 3526 (VEEV) VEE TC-83 (VEEV) |
Valneva DynPort Vaccine USAMRIID |
|
| Inactivated |
BBV87 (CHIKV) TSI-GSD 104 (EEEV) VEE C-84 (VEEV) TSI-GSD 210 (WEEV) |
Bharat Biotech USAMRIID USAMRIID USAMRIID |
|
| Virus-like particle |
VRC-CHKVLP059 (CHIKV) PXVX0317 (CHIKV) VRC-WEVVLP073 (EEEV/VEEV/WEEV) |
NIH/NIAID Emergent BioSolutions NIH/NIAID |
|
| Viral vector |
MV-CHIK (CHIKV) ChAdOx1 Chik (CHIKV) |
Themis Bioscience University of Oxford |
|
| mRNA-based | mRNA-1944 (CHIKV) | Moderna | NCT03829384 |
CHIKV, chikungunya virus; EEEV, Eastern equine encephalitis virus; NIAID, National Institute of Allergy and Infectious Diseases; USAMRIID, United States Army Medical Research Institute of Infectious Diseases; VEEV, Venezuelan equine encephalitis virus; WEEV, Western equine encephalitis virus.